GlassScriptPhysician profile
Gerald Van Jones
NPI 1649276650
$1,380.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $206 · 2021: $470 · 2022: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $312.36 | 2019-2021 | |
| Akebia Therapeutics INC | $269.28 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $189.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $150.33 | 2019-2022 | |
| Amgen INC. | $118.98 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.78 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $46.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.28 | 2022 | |
| Fresenius USA Marketing, INC. | $39.04 | 2022 | |
| Lundbeck LLC | $31.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.58 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $24.98 | 2022 | |
| Daiichi Sankyo INC. | $20.88 | 2021 | |
| Shire North American Group INC | $16.93 | 2019 | |
| Glaxosmithkline, LLC. | $14.12 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $13.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.